An experimental lung cancer drug developed by Akeso and licensed globally by Summit Therapeutics delivered one of the most closely watched oncology results of the year. The drug reduced the risk of death by 34% during a late-stage clinical trial conducted in China. As a result, the findings immediately intensified discussions across the pharmaceutical industry about whether a new generation of cancer therapies could eventually challenge dominant treatments such as
